RT Journal Article
SR Electronic
T1 Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3719
DO 10.1183/13993003.congress-2019.PA3719
VO 54
IS suppl 63
A1 J. Christian Virchow
A1 Pierluigi Paggiaro
A1 Walter Giorgio Canonica
A1 Piotr Kuna
A1 Maxim Kots
A1 Sandrine Corre
A1 Andrea Vele
A1 George Georges
A1 Stefano Petruzzelli
YR 2019
UL http://erj.ersjournals.com/content/54/suppl_63/PA3719.abstract
AB Introduction: Persistent airflow limitation (PAL) may predict a positive clinical response to add-on long-acting muscarinic antagonist (LAMA) in patients with asthma taking inhaled corticosteroids and long-acting β2-receptor agonists (ICS/LABA).Aims and Objectives: We evaluated the effect of extrafine MS beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) on asthma exacerbations in a subset of patients with PAL.Methods: TRIMARAN was a phase III multinational, randomized, parallel group trial comparing 52-week treatment with (BDP/FF/GB) 400/24/50 µg/d to BDP/FF 400/24 µg/d delivered via a pressurized metered dose inhaler (pMDI) in adult patients with uncontrolled asthma on medium dose ICS/LABA and a history of exacerbation in the past year. PAL was defined as an FEV1 ≤80% of predicted normal and FEV1/FVC ≤0.7 after 400 μg salbutamol pMDI.Results: 1155 subjects were randomized and 658 (57.0%) met the PAL criteria on BDP/FF/GB (n=331) and BDP/FF (n=327), respectively. Treatment of this subgroup with BDP/FF/GB compared to BDP/FF resulted in a 15.2% and 37.7% reduction in the annual rates of moderate-severe and severe asthma exacerbations respectively, (RR [95% CI] = 0.848 [0.694, 1.036], p=0.106; 0.623 [0.430; 0.902], p=0.012), vs. 15.4% (p=0.033) and 26.3% (p=0.040) reduction in the entire study population.Conclusions: In patients with asthma uncontrolled on medium dose ICS/LABA, PAL did not influence the efficacy of extrafine MS BDP/FF/GB in reducing moderate-severe exacerbations and was associated with a greater reduction in annual severe exacerbation rates.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA3719.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).